Zolgensma Creation Story Reveals Truths About Drug Pricing — ProPublica

Reporting Highlights

• A Record Price: The gene therapy Zolgensma helped children born with a fatal disease, spinal muscular atrophy, grow up to run and play. But the cost was stunning: $2 million per dose.
• Cashing In: While taxpayers and small charities funded the drug's early development, executives, venture-capital backers and a pharma giant have reaped the profits.
• Priced Out: The drug's cost adds to the nation's ballooning bill for prescription drugs and puts Zolgensma out of reach for kids in many low- and middle-income countries.

https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis